Page last updated: 2024-12-07

quinaprilat

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Quinaprilat is a potent, long-acting angiotensin-converting enzyme (ACE) inhibitor, produced by the hydrolysis of the prodrug quinapril. It is a competitive inhibitor of ACE, which is responsible for the conversion of angiotensin I to angiotensin II. Angiotensin II is a potent vasoconstrictor that increases blood pressure. By inhibiting ACE, quinaprilat reduces the production of angiotensin II, leading to vasodilation and a decrease in blood pressure. It is used to treat hypertension and heart failure, and also in the prevention of stroke in patients with high risk. Quinaprilat has been studied for its potential to improve cardiovascular outcomes in patients with chronic kidney disease and diabetes. The drug has been shown to be effective in reducing blood pressure, slowing the progression of kidney disease, and reducing the risk of cardiovascular events in these patients.'

quinaprilat: metabolite of quinapril [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

quinaprilat : A dicarboxylic acid resulting from the hydrolysis of the ethyl ester group of quinapril to give the corresponding dicarboxylic acid. The active angiotensin-converting enzyme inhibitor (ACE inhibitor) of the prodrug quinapril. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID107994
CHEMBL ID1733
CHEBI ID140296
SCHEMBL ID113237
MeSH IDM0153856

Synonyms (55)

Synonym
2-(2-((1-carboxy-3-phenylpropyl)amino)-1-oxopropyl)-1,2,3,4-tetrahydro-3-isoquinolinecarboxylic acid
ci-928
3-isoquinolinecarboxylic acid, 2-((2s)-2-(((1s)-1-carboxy-3-phenylpropyl)amino)-1-oxopropyl)-1,2,3,4-tetrahydro-, (3s)-
3-isoquinolinecarboxylic acid, 2-(2-((1-carboxy-3-phenylpropyl)amino)-1-oxopropyl)-1,2,3,4-tetrahydro-, (3s-(2(r*(r*)),3r*))-
3-isoquinolinecarboxylic acid, 1,2,3,4-tetrahydro-2-(2-((1-carboxy-3-phenylpropyl)amino)-1-oxopropyl)-, (3s-(2(r*(r*)),3r*))-
quinaprilat
quinaprilat [usan:inn]
brn 5653070
ci 928
D03773
quinaprilat (usan/inn)
quinaprilate
ci928
82768-85-2
cl-928
quinaprilatum
(3s)-2-{n-[(1s)-1-carboxy-3-phenylpropyl]-l-alanyl}-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid
CHEBI:140296 ,
CHEMBL1733
quinapril diacid
nsc-759825
(3s)-2-[(2s)-2-[[(2s)-1-hydroxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-3,4-dihydro-1h-isoquinoline-3-carboxylic acid
HMS3264B04
pharmakon1600-01505455
nsc759825
bdbm50367258
34ssx5lde5 ,
unii-34ssx5lde5
nsc 759825
quinapril hydrochloride impurity c [ep impurity]
quinaprilat [usan]
quinaprilat [inn]
(3s)-2-[(s)-n-[(s)-1-carboxy-3-phenylpropyl]alanyl]-1,2,3,4-tetrahydro-3-isoquinolinecarboxylic acid
quinaprilat [who-dd]
gtpl6352
CCG-213212
SCHEMBL113237
AB01563002_01
(3s)-2-[(2s)-2-{[(1s)-1-carboxy-3-phenylpropyl]amino}propanoyl]-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid
C21540
HY-127026
(3s)-2-[(2s)-2-[[(1s)-1-carboxy-3-phenylpropyl]amino]propanoyl]-3,4-dihydro-1h-isoquinoline-3-carboxylic acid
DTXSID40868904 ,
DB14217
Q7272073
(s)-2-(((s)-1-carboxy-3-phenylpropyl)-l-alanyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid
(3s)-2-[(2s)-2-[[(1s)-1-carboxy-3-phenylpropyl]amino]propanoyl]-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid (quinaprilat)
(s)-2-(((s)-1-carboxy-3-phenylpropyl)-l-alanyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxylicacid
usp quinapril related compound b
CS-0091681
(3s)-2-((s)-n-((s)-1-carboxy-3-phenylpropyl)alanyl)-1,2,3,4-tetrahydro-3-isoquinolinecarboxylic acid
(3s)-2-(n-((1s)-1-carboxy-3-phenylpropyl)-l-alanyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid
dtxcid30820879
quinapril hydrochloride impurity c (ep impurity)
AKOS040744756

Research Excerpts

Overview

Quinaprilat is a potent nonsulfhydryl selective ACE inhibitor with a short elimination half-life of 2 - 3 h. Once daily dosing is sufficient for effective ACE inhibition.

ExcerptReferenceRelevance
"Quinaprilat is an ACE inhibitor for intravenous use especially in patients with arterial hypertension or chronic heart failure. "( Quinaprilat: a review of its pharmacokinetics, pharmacodynamics, toxicological data and clinical application.
Felix, SB; Kieback, AG; Reffelmann, T, 2009
)
3.24
"Quinaprilat is a potent nonsulfhydryl selective ACE inhibitor with a short elimination half-life of 2 - 3 h, but due to slow dissociation from tissue ACE, once daily dosing is sufficient for effective ACE inhibition. "( Quinaprilat: a review of its pharmacokinetics, pharmacodynamics, toxicological data and clinical application.
Felix, SB; Kieback, AG; Reffelmann, T, 2009
)
3.24
"Quinaprilat is an attractive ACE inhibitor, which potently inhibits tissue ACE."( Quinaprilat: a review of its pharmacokinetics, pharmacodynamics, toxicological data and clinical application.
Felix, SB; Kieback, AG; Reffelmann, T, 2009
)
3.24

Treatment

ExcerptReferenceRelevance
"In quinaprilat-treated SHRSP, SBP was lowered to 135+/-5 mm Hg."( Regulation of pressure-activated channel in intact vascular endothelium of stroke-prone spontaneously hypertensive rats.
Brakemeier, S; Distler, A; Grundig, A; Hoyer, J; Köhler, R; Kreutz, R; Rothermund, L, 2001
)
0.82

Pharmacokinetics

Quinaprilat was detectable in plasma up to 72 hours after all doses and the terminal phase half-life was calculated at 26 +/- 7 hours. Increases in the apparent elimination half- life and in AUC(0, 12h) were associated with smaller ejection fractions, decreased creatinine clearance, and increased patient age.

ExcerptReferenceRelevance
" Quinaprilat was detectable in plasma up to 72 hours after all doses and the terminal phase half-life was calculated at 26 +/- 7 hours."( Dose responses and pharmacokinetics for the angiotensin converting enzyme inhibitor quinapril.
Elliott, HL; Macdonald, NJ; Meredith, PA; Reid, JL, 1992
)
1.19
" In contrast, quinaprilat maximum plasma concentration, trough and peak steady-state plasma concentrations, area under the plasma concentration-time curve, and half-life increased significantly with increasing renal insufficiency."( The pharmacokinetics of quinapril and its active metabolite, quinaprilat, in patients with various degrees of renal function.
Abraham, PA; Halstenson, CE; Horvath, AM; Olson, SC; Opsahl, JA; Posvar, EL; Rachael, K, 1992
)
0.89
" The pharmacokinetic profile of quinapril in these CAPD patients was not significantly different from that previously observed in healthy subjects with normal renal function and in patients with moderate to severe renal dysfunction not yet requiring dialysis (RDND)."( Pharmacokinetics of quinapril and its active metabolite quinaprilat during continuous ambulatory peritoneal dialysis.
Horvath, AM; Olson, SC; Posvar, EL; Starmann, B; Swartz, RD, 1990
)
0.53
" Comparable mean quinapril pharmacokinetic parameter values as well as comparable mean quinaprilat pharmacokinetic parameter values determined following quinapril administered alone and following quinapril administered with propranolol, indicate that propranolol does not alter the single dose pharmacokinetics of quinapril or quinaprilat."( Multiple-dose propranolol administration does not influence the single dose pharmacokinetics of quinapril and its active metabolite (quinaprilat).
Caillé, G; Colburn, WA; Ferry, JJ; Frank, GJ; Horvath, AM; Lacasse, Y; Olson, SC; Pilon, D, 1990
)
0.71
" Peak plasma concentrations of these metabolites are similar to that of Q, and each is eliminated rapidly with a half-life of approximately one hour."( The clinical pharmacokinetics of quinapril.
Colburn, WA; Horvath, AM; Michniewicz, BM; Olson, SC; Sedman, AJ; Welling, PG, 1989
)
0.28
"The potential effect of cimetidine on the pharmacokinetic profiles of quinapril and its active metabolite CI-928 was evaluated in eight healthy volunteers."( Multiple-dose cimetidine administration does not influence the single-dose pharmacokinetics of quinapril and its active metabolite (CI-928).
Cetnarowski, AB; Ferry, JJ; Horvath, AM; Sedman, AJ; Thomas, RW, 1988
)
0.27
"5 hour in quinapril and CI-928 tmax values were observed after consumption of food."( Influence of food on the pharmacokinetics of quinapril and its active diacid metabolite, CI-928.
Colburn, WA; Ferry, JJ; Horvath, AM; Latts, JR; Sedman, AJ,
)
0.13
" Increases in the apparent elimination half-life and in AUC(0, 12h) values of quinaprilat were associated with smaller ejection fractions, decreased creatinine clearance, and increased patient age."( The pharmacokinetics of quinapril and quinaprilat in patients with congestive heart failure.
Bammert-Adams, JA; Begg, EJ; Ikram, H; Olson, SC; Posvar, EL; Reece, PA; Richards, AM; Robson, RA; Sedman, AJ, 1994
)
0.79
" Pharmacodynamic effects of quinaprilat and oral quinapril were assessed by measurement of blood pressure changes after an infusion of angiotensin I (A-I) at a dose previously determined to produce an increase in diastolic blood pressure of 25 mmHg under standardized conditions (A-I pressor response)."( A pharmacodynamic and pharmacokinetic comparison of intravenous quinaprilat and oral quinapril.
Breslin, E; Jahnchen, E; Neub, M; Posvar, E; Trenk, D, 1996
)
0.83
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35
" The pharmacokinetic parameters were analyzed by noncompartmental analysis and the ANOVA was carried out using logarithmically transformed data of the AUC and C as well as untransformed T(max)."( Pharmacokinetics and bioequivalence study of the two 20-mg quinapril hydrochloride tablet formulations in healthy Thai male volunteers.
Jengjareon, A; Kumsorn, B; Nasangiam, N; Rojanasthien, N; Roongapinun, S, 2008
)
0.35
" The half-life of quinapril (1."( Pharmacokinetics and bioequivalence study of the two 20-mg quinapril hydrochloride tablet formulations in healthy Thai male volunteers.
Jengjareon, A; Kumsorn, B; Nasangiam, N; Rojanasthien, N; Roongapinun, S, 2008
)
0.35
"In this review, the pharmacokinetic and pharmacodynamic profile of quinaprilat as well as toxicological data and results of preclinical and clinical studies are summarized."( Quinaprilat: a review of its pharmacokinetics, pharmacodynamics, toxicological data and clinical application.
Felix, SB; Kieback, AG; Reffelmann, T, 2009
)
2.03
"Quinaprilat is a potent nonsulfhydryl selective ACE inhibitor with a short elimination half-life of 2 - 3 h, but due to slow dissociation from tissue ACE, once daily dosing is sufficient for effective ACE inhibition."( Quinaprilat: a review of its pharmacokinetics, pharmacodynamics, toxicological data and clinical application.
Felix, SB; Kieback, AG; Reffelmann, T, 2009
)
3.24
" Noncompartmental pharmacokinetic modelling and statistical analyses were performed."( Effects of quinapril on angiotensin converting enzyme and plasma renin activity as well as pharmacokinetic parameters of quinapril and its active metabolite, quinaprilat, after intravenous and oral administration to mature horses.
Barlow, BM; Breuhaus, BA; Davis, JL; Kruger, K; LaFevers, DH; Schirmer, JM, 2014
)
0.6
" The CES1 genotype had no significant effect on the enalaprilat to enalapril AUC0-∞ ratio or on any other pharmacokinetic or pharmacodynamic parameters of enalapril or enalaprilat."( Effect of carboxylesterase 1 c.428G > A single nucleotide variation on the pharmacokinetics of quinapril and enalapril.
Backman, JT; Holmberg, MT; Launiainen, T; Neuvonen, PJ; Niemi, M; Tarkiainen, EK; Tornio, A, 2015
)
0.42

Bioavailability

ExcerptReferenceRelevance
" Based on the concentrations of quinaprilat observed in this study, the absolute bioavailability of quinapril was approximately 50%; intravenous quinaprilat should therefore produce a pharmacodynamic response similar to that obtained with oral quinapril at approximately half the dose."( A pharmacodynamic and pharmacokinetic comparison of intravenous quinaprilat and oral quinapril.
Breslin, E; Jahnchen, E; Neub, M; Posvar, E; Trenk, D, 1996
)
0.82
"Oral bioavailability (F) is a product of fraction absorbed (Fa), fraction escaping gut-wall elimination (Fg), and fraction escaping hepatic elimination (Fh)."( Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV, 2010
)
0.36
" Bioavailability of quinapril following oral administration was <5%."( Effects of quinapril on angiotensin converting enzyme and plasma renin activity as well as pharmacokinetic parameters of quinapril and its active metabolite, quinaprilat, after intravenous and oral administration to mature horses.
Barlow, BM; Breuhaus, BA; Davis, JL; Kruger, K; LaFevers, DH; Schirmer, JM, 2014
)
0.6

Dosage Studied

Quinaprilat is a potent nonsulfhydryl selective ACE inhibitor with a short elimination half-life of 2 - 3 h. Due to slow dissociation from tissue ACE, once daily dosing is sufficient for effective ACE inhibition.

ExcerptRelevanceReference
"5 mg to produce any further increase in the magnitude of ACE inhibition is consistent with an maximum effect dose-response relationship, with the obvious implication that higher doses will increase only the duration not the magnitude of response."( Dose responses and pharmacokinetics for the angiotensin converting enzyme inhibitor quinapril.
Elliott, HL; Macdonald, NJ; Meredith, PA; Reid, JL, 1992
)
0.28
" Thus, quinapril dosage adjustment may be required in some patients with renal impairment."( The pharmacokinetics of quinapril and its active metabolite, quinaprilat, in patients with various degrees of renal function.
Abraham, PA; Halstenson, CE; Horvath, AM; Olson, SC; Opsahl, JA; Posvar, EL; Rachael, K, 1992
)
0.52
" These results suggest that the dosage rate of quinapril may have to be altered in renal impairment."( The pharmacokinetics and pharmacodynamics of quinapril and quinaprilat in renal impairment.
Bailey, RR; Begg, EJ; Frank, GJ; Lynn, KL; Olson, SC; Robson, RA, 1990
)
0.52
" Blood pressure reduction was observed in four of six patients, with onset reliably two to four hours after dosing and duration up to 48 hours, associated with quinaprilat concentrations in plasma above 90 ng/mL for at least 33 hours postdose."( Pharmacokinetics of quinapril and its active metabolite quinaprilat during continuous ambulatory peritoneal dialysis.
Horvath, AM; Olson, SC; Posvar, EL; Starmann, B; Swartz, RD, 1990
)
0.72
" Dosing of quinapril in patients with CHF should be based on their renal function."( The pharmacokinetics of quinapril and quinaprilat in patients with congestive heart failure.
Bammert-Adams, JA; Begg, EJ; Ikram, H; Olson, SC; Posvar, EL; Reece, PA; Richards, AM; Robson, RA; Sedman, AJ, 1994
)
0.56
" Hemodynamic changes after multiple-dose quinaprilat administration were similar to those observed after single doses and were generally sustained during the 6-hour dosing interval."( Hemodynamic and hormonal effects of quinaprilat in patients with congestive heart failure.
Bakovic-Alt, R; Bonzel, T; Mitrovic, V; Mudra, H; Posvar, EL; Schmidt, W; Strand, JC, 1996
)
0.83
" The dose-response and duration-of-effect after single intravenous doses of quinaprilat and placebo (part A) and after administration of oral quinapril solution and intravenous quinaprilat (part B) were assessed in a randomized, crossover study of two groups of 12 healthy volunteers."( A pharmacodynamic and pharmacokinetic comparison of intravenous quinaprilat and oral quinapril.
Breslin, E; Jahnchen, E; Neub, M; Posvar, E; Trenk, D, 1996
)
0.76
" Further, the urinary recovery of quinapril and quinaprilat (after dosing quinapril into proximal segments) was urine flow rate dependent."( Reabsorption and metabolism of quinapril and quinaprilat in rat kidney: in vivo micropuncture studies.
Kugler, AR; Schnermann, JB; Smith, DE, 1995
)
0.81
" Two patients treated with quinaprilat withdrew due to hypotension; one patient required a dosage reduction."( Assessing the clinical need for short-term conversion from oral to parenteral angiotensin converting enzyme inhibitor therapy in hypertensive patients. A quinapril to quinaprilat placebo-controlled model.
Canter, D; Goldstein, R; McCormick, L; Whelton, A; Wombolt, D, 1997
)
0.79
" Serial plasma concentrations of quinapril and its active metabolite quinaprilat up to 24 h after dosing were determined by HPLC with UV detection."( Pharmacokinetics and bioequivalence study of the two 20-mg quinapril hydrochloride tablet formulations in healthy Thai male volunteers.
Jengjareon, A; Kumsorn, B; Nasangiam, N; Rojanasthien, N; Roongapinun, S, 2008
)
0.58
"Quinaprilat is a potent nonsulfhydryl selective ACE inhibitor with a short elimination half-life of 2 - 3 h, but due to slow dissociation from tissue ACE, once daily dosing is sufficient for effective ACE inhibition."( Quinaprilat: a review of its pharmacokinetics, pharmacodynamics, toxicological data and clinical application.
Felix, SB; Kieback, AG; Reffelmann, T, 2009
)
3.24
"5 ng/ml) for most horses in the 120 mg dosing group."( Effects of quinapril on angiotensin converting enzyme and plasma renin activity as well as pharmacokinetic parameters of quinapril and its active metabolite, quinaprilat, after intravenous and oral administration to mature horses.
Barlow, BM; Breuhaus, BA; Davis, JL; Kruger, K; LaFevers, DH; Schirmer, JM, 2014
)
0.6
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitorAn EC 3.4.15.* (peptidyl-dipeptidase) inhibitor that interferes with the action of peptidyl-dipeptidase A (EC 3.4.15.1).
antihypertensive agentAny drug used in the treatment of acute or chronic vascular hypertension regardless of pharmacological mechanism.
vasodilator agentA drug used to cause dilation of the blood vessels.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
dicarboxylic acidAny carboxylic acid containing two carboxy groups.
isoquinolinesA class of organic heteropolycyclic compound consisting of isoquinoline and its substitution derivatives.
tertiary carboxamideA carboxamide resulting from the formal condensation of a carboxylic acid with a secondary amine; formula RC(=O)NHR(1)R(2).
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (2)

PathwayProteinsCompounds
Quinapril Action Pathway34
Quinapril Metabolism Pathway12

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Angiotensin-converting enzyme Homo sapiens (human)IC50 (µMol)0.05830.00010.533610.0000AID38858; AID39750; AID39758
Angiotensin-converting enzyme 2 Homo sapiens (human)IC50 (µMol)0.00280.00042.207910.0000AID39758
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (78)

Processvia Protein(s)Taxonomy
response to hypoxiaAngiotensin-converting enzyme Homo sapiens (human)
kidney developmentAngiotensin-converting enzyme Homo sapiens (human)
blood vessel remodelingAngiotensin-converting enzyme Homo sapiens (human)
angiotensin maturationAngiotensin-converting enzyme Homo sapiens (human)
regulation of renal output by angiotensinAngiotensin-converting enzyme Homo sapiens (human)
neutrophil mediated immunityAngiotensin-converting enzyme Homo sapiens (human)
antigen processing and presentation of peptide antigen via MHC class IAngiotensin-converting enzyme Homo sapiens (human)
regulation of systemic arterial blood pressure by renin-angiotensinAngiotensin-converting enzyme Homo sapiens (human)
proteolysisAngiotensin-converting enzyme Homo sapiens (human)
spermatogenesisAngiotensin-converting enzyme Homo sapiens (human)
female pregnancyAngiotensin-converting enzyme Homo sapiens (human)
regulation of blood pressureAngiotensin-converting enzyme Homo sapiens (human)
male gonad developmentAngiotensin-converting enzyme Homo sapiens (human)
response to xenobiotic stimulusAngiotensin-converting enzyme Homo sapiens (human)
embryo development ending in birth or egg hatchingAngiotensin-converting enzyme Homo sapiens (human)
post-transcriptional regulation of gene expressionAngiotensin-converting enzyme Homo sapiens (human)
negative regulation of gene expressionAngiotensin-converting enzyme Homo sapiens (human)
substance P catabolic processAngiotensin-converting enzyme Homo sapiens (human)
bradykinin catabolic processAngiotensin-converting enzyme Homo sapiens (human)
regulation of smooth muscle cell migrationAngiotensin-converting enzyme Homo sapiens (human)
regulation of vasoconstrictionAngiotensin-converting enzyme Homo sapiens (human)
animal organ regenerationAngiotensin-converting enzyme Homo sapiens (human)
response to nutrient levelsAngiotensin-converting enzyme Homo sapiens (human)
response to lipopolysaccharideAngiotensin-converting enzyme Homo sapiens (human)
mononuclear cell proliferationAngiotensin-converting enzyme Homo sapiens (human)
response to laminar fluid shear stressAngiotensin-converting enzyme Homo sapiens (human)
angiotensin-activated signaling pathwayAngiotensin-converting enzyme Homo sapiens (human)
vasoconstrictionAngiotensin-converting enzyme Homo sapiens (human)
hormone metabolic processAngiotensin-converting enzyme Homo sapiens (human)
hormone catabolic processAngiotensin-converting enzyme Homo sapiens (human)
eating behaviorAngiotensin-converting enzyme Homo sapiens (human)
positive regulation of apoptotic processAngiotensin-converting enzyme Homo sapiens (human)
peptide catabolic processAngiotensin-converting enzyme Homo sapiens (human)
positive regulation of vasoconstrictionAngiotensin-converting enzyme Homo sapiens (human)
negative regulation of glucose importAngiotensin-converting enzyme Homo sapiens (human)
regulation of synaptic plasticityAngiotensin-converting enzyme Homo sapiens (human)
lung alveolus developmentAngiotensin-converting enzyme Homo sapiens (human)
amyloid-beta metabolic processAngiotensin-converting enzyme Homo sapiens (human)
arachidonic acid secretionAngiotensin-converting enzyme Homo sapiens (human)
positive regulation of neurogenesisAngiotensin-converting enzyme Homo sapiens (human)
heart contractionAngiotensin-converting enzyme Homo sapiens (human)
regulation of angiotensin metabolic processAngiotensin-converting enzyme Homo sapiens (human)
hematopoietic stem cell differentiationAngiotensin-converting enzyme Homo sapiens (human)
angiogenesis involved in coronary vascular morphogenesisAngiotensin-converting enzyme Homo sapiens (human)
cellular response to glucose stimulusAngiotensin-converting enzyme Homo sapiens (human)
response to dexamethasoneAngiotensin-converting enzyme Homo sapiens (human)
cell proliferation in bone marrowAngiotensin-converting enzyme Homo sapiens (human)
regulation of heart rate by cardiac conductionAngiotensin-converting enzyme Homo sapiens (human)
negative regulation of calcium ion importAngiotensin-converting enzyme Homo sapiens (human)
response to thyroid hormoneAngiotensin-converting enzyme Homo sapiens (human)
blood vessel diameter maintenanceAngiotensin-converting enzyme Homo sapiens (human)
regulation of hematopoietic stem cell proliferationAngiotensin-converting enzyme Homo sapiens (human)
negative regulation of gap junction assemblyAngiotensin-converting enzyme Homo sapiens (human)
cellular response to aldosteroneAngiotensin-converting enzyme Homo sapiens (human)
positive regulation of peptidyl-cysteine S-nitrosylationAngiotensin-converting enzyme Homo sapiens (human)
positive regulation of systemic arterial blood pressureAngiotensin-converting enzyme Homo sapiens (human)
negative regulation of signaling receptor activityAngiotensin-converting enzyme 2 Homo sapiens (human)
symbiont entry into host cellAngiotensin-converting enzyme 2 Homo sapiens (human)
regulation of cytokine productionAngiotensin-converting enzyme 2 Homo sapiens (human)
angiotensin maturationAngiotensin-converting enzyme 2 Homo sapiens (human)
angiotensin-mediated drinking behaviorAngiotensin-converting enzyme 2 Homo sapiens (human)
regulation of systemic arterial blood pressure by renin-angiotensinAngiotensin-converting enzyme 2 Homo sapiens (human)
tryptophan transportAngiotensin-converting enzyme 2 Homo sapiens (human)
viral life cycleAngiotensin-converting enzyme 2 Homo sapiens (human)
receptor-mediated endocytosis of virus by host cellAngiotensin-converting enzyme 2 Homo sapiens (human)
regulation of vasoconstrictionAngiotensin-converting enzyme 2 Homo sapiens (human)
regulation of transmembrane transporter activityAngiotensin-converting enzyme 2 Homo sapiens (human)
regulation of cell population proliferationAngiotensin-converting enzyme 2 Homo sapiens (human)
symbiont entry into host cellAngiotensin-converting enzyme 2 Homo sapiens (human)
receptor-mediated virion attachment to host cellAngiotensin-converting enzyme 2 Homo sapiens (human)
negative regulation of smooth muscle cell proliferationAngiotensin-converting enzyme 2 Homo sapiens (human)
regulation of inflammatory responseAngiotensin-converting enzyme 2 Homo sapiens (human)
positive regulation of amino acid transportAngiotensin-converting enzyme 2 Homo sapiens (human)
maternal process involved in female pregnancyAngiotensin-converting enzyme 2 Homo sapiens (human)
positive regulation of cardiac muscle contractionAngiotensin-converting enzyme 2 Homo sapiens (human)
membrane fusionAngiotensin-converting enzyme 2 Homo sapiens (human)
negative regulation of ERK1 and ERK2 cascadeAngiotensin-converting enzyme 2 Homo sapiens (human)
blood vessel diameter maintenanceAngiotensin-converting enzyme 2 Homo sapiens (human)
entry receptor-mediated virion attachment to host cellAngiotensin-converting enzyme 2 Homo sapiens (human)
positive regulation of gap junction assemblyAngiotensin-converting enzyme 2 Homo sapiens (human)
regulation of cardiac conductionAngiotensin-converting enzyme 2 Homo sapiens (human)
positive regulation of L-proline import across plasma membraneAngiotensin-converting enzyme 2 Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processAngiotensin-converting enzyme 2 Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (20)

Processvia Protein(s)Taxonomy
endopeptidase activityAngiotensin-converting enzyme Homo sapiens (human)
carboxypeptidase activityAngiotensin-converting enzyme Homo sapiens (human)
metalloendopeptidase activityAngiotensin-converting enzyme Homo sapiens (human)
calmodulin bindingAngiotensin-converting enzyme Homo sapiens (human)
peptidase activityAngiotensin-converting enzyme Homo sapiens (human)
metallopeptidase activityAngiotensin-converting enzyme Homo sapiens (human)
exopeptidase activityAngiotensin-converting enzyme Homo sapiens (human)
tripeptidyl-peptidase activityAngiotensin-converting enzyme Homo sapiens (human)
peptidyl-dipeptidase activityAngiotensin-converting enzyme Homo sapiens (human)
zinc ion bindingAngiotensin-converting enzyme Homo sapiens (human)
chloride ion bindingAngiotensin-converting enzyme Homo sapiens (human)
mitogen-activated protein kinase kinase bindingAngiotensin-converting enzyme Homo sapiens (human)
bradykinin receptor bindingAngiotensin-converting enzyme Homo sapiens (human)
mitogen-activated protein kinase bindingAngiotensin-converting enzyme Homo sapiens (human)
metallodipeptidase activityAngiotensin-converting enzyme Homo sapiens (human)
heterocyclic compound bindingAngiotensin-converting enzyme Homo sapiens (human)
virus receptor activityAngiotensin-converting enzyme 2 Homo sapiens (human)
endopeptidase activityAngiotensin-converting enzyme 2 Homo sapiens (human)
carboxypeptidase activityAngiotensin-converting enzyme 2 Homo sapiens (human)
metallocarboxypeptidase activityAngiotensin-converting enzyme 2 Homo sapiens (human)
protein bindingAngiotensin-converting enzyme 2 Homo sapiens (human)
metallopeptidase activityAngiotensin-converting enzyme 2 Homo sapiens (human)
peptidyl-dipeptidase activityAngiotensin-converting enzyme 2 Homo sapiens (human)
zinc ion bindingAngiotensin-converting enzyme 2 Homo sapiens (human)
identical protein bindingAngiotensin-converting enzyme 2 Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (17)

Processvia Protein(s)Taxonomy
extracellular spaceAngiotensin-converting enzyme Homo sapiens (human)
extracellular regionAngiotensin-converting enzyme Homo sapiens (human)
extracellular spaceAngiotensin-converting enzyme Homo sapiens (human)
lysosomeAngiotensin-converting enzyme Homo sapiens (human)
endosomeAngiotensin-converting enzyme Homo sapiens (human)
plasma membraneAngiotensin-converting enzyme Homo sapiens (human)
external side of plasma membraneAngiotensin-converting enzyme Homo sapiens (human)
basal plasma membraneAngiotensin-converting enzyme Homo sapiens (human)
brush border membraneAngiotensin-converting enzyme Homo sapiens (human)
extracellular exosomeAngiotensin-converting enzyme Homo sapiens (human)
sperm midpieceAngiotensin-converting enzyme Homo sapiens (human)
plasma membraneAngiotensin-converting enzyme Homo sapiens (human)
plasma membraneAngiotensin-converting enzyme 2 Homo sapiens (human)
extracellular regionAngiotensin-converting enzyme 2 Homo sapiens (human)
extracellular spaceAngiotensin-converting enzyme 2 Homo sapiens (human)
endoplasmic reticulum lumenAngiotensin-converting enzyme 2 Homo sapiens (human)
plasma membraneAngiotensin-converting enzyme 2 Homo sapiens (human)
ciliumAngiotensin-converting enzyme 2 Homo sapiens (human)
cell surfaceAngiotensin-converting enzyme 2 Homo sapiens (human)
membraneAngiotensin-converting enzyme 2 Homo sapiens (human)
apical plasma membraneAngiotensin-converting enzyme 2 Homo sapiens (human)
endocytic vesicle membraneAngiotensin-converting enzyme 2 Homo sapiens (human)
brush border membraneAngiotensin-converting enzyme 2 Homo sapiens (human)
membrane raftAngiotensin-converting enzyme 2 Homo sapiens (human)
extracellular exosomeAngiotensin-converting enzyme 2 Homo sapiens (human)
extracellular spaceAngiotensin-converting enzyme 2 Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (28)

Assay IDTitleYearJournalArticle
AID39750In vitro inhibitory activity against Angiotensin I converting enzyme from unpurified guinea pig serum1985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Synthesis and biological activity of modified peptide inhibitors of angiotensin-converting enzyme.
AID186366Baseline mean aortic blood pressure in conscious renal (1clip/2kidney) hypertensive rats at dose 3 mg/kg administered orally.1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Synthesis of novel angiotensin converting enzyme inhibitor quinapril and related compounds. A divergence of structure-activity relationships for non-sulfhydryl and sulfhydryl types.
AID186543Maximum change aortic blood pressure in conscious renal (1clip/2kidney) hypertensive rats at dose 10 mg/kg administered orally at 5 hr.1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Synthesis of novel angiotensin converting enzyme inhibitor quinapril and related compounds. A divergence of structure-activity relationships for non-sulfhydryl and sulfhydryl types.
AID444058Volume of distribution at steady state in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID186685Maximum change aortic blood pressure in conscious renal (1clip/2kidney) hypertensive rats at dose 3 mg/kg administered orally at 2 hr.1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Synthesis of novel angiotensin converting enzyme inhibitor quinapril and related compounds. A divergence of structure-activity relationships for non-sulfhydryl and sulfhydryl types.
AID186360Baseline mean aortic blood pressure in conscious renal (1clip/2kidney) hypertensive rats at dose 10 mg/kg administered orally.1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Synthesis of novel angiotensin converting enzyme inhibitor quinapril and related compounds. A divergence of structure-activity relationships for non-sulfhydryl and sulfhydryl types.
AID444057Fraction escaping hepatic elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID186365Baseline mean aortic blood pressure in conscious renal (1clip/2kidney) hypertensive rats at dose 30 mg/kg administered orally.1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Synthesis of novel angiotensin converting enzyme inhibitor quinapril and related compounds. A divergence of structure-activity relationships for non-sulfhydryl and sulfhydryl types.
AID186675Maximum change aortic blood pressure in conscious renal (1clip/2kidney) hypertensive rats at dose 1 mg/kg administered orally at 7 hr.1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Synthesis of novel angiotensin converting enzyme inhibitor quinapril and related compounds. A divergence of structure-activity relationships for non-sulfhydryl and sulfhydryl types.
AID444051Total clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID39758Inhibition of guinea pig angiotensin I converting enzyme1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Synthesis of novel angiotensin converting enzyme inhibitor quinapril and related compounds. A divergence of structure-activity relationships for non-sulfhydryl and sulfhydryl types.
AID444052Hepatic clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID444055Fraction absorbed in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID444056Fraction escaping gut-wall elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID444054Oral bioavailability in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID444050Fraction unbound in human plasma2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID38858Compound was tested for its inhibitory potency against angiotensin I converting enzyme1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
Molecular and crystal structures of MDL27,467A hydrochloride and quinapril hydrochloride, two ester derivatives of potent angiotensin converting enzyme inhibitors.
AID425652Total body clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID444053Renal clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID186684Maximum change aortic blood pressure in conscious renal (1clip/2kidney) hypertensive rats at dose 30 mg/kg administered orally at 9 hr.1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Synthesis of novel angiotensin converting enzyme inhibitor quinapril and related compounds. A divergence of structure-activity relationships for non-sulfhydryl and sulfhydryl types.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID186362Baseline mean aortic blood pressure in conscious renal (1clip/2kidney) hypertensive rats at dose 1 mg/kg administered orally.1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Synthesis of novel angiotensin converting enzyme inhibitor quinapril and related compounds. A divergence of structure-activity relationships for non-sulfhydryl and sulfhydryl types.
AID425653Renal clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1345457Human Angiotensin-converting enzyme (M2: Angiotensin-converting (ACE and ACE2))1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
Molecular and crystal structures of MDL27,467A hydrochloride and quinapril hydrochloride, two ester derivatives of potent angiotensin converting enzyme inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (87)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (4.60)18.7374
1990's41 (47.13)18.2507
2000's36 (41.38)29.6817
2010's5 (5.75)24.3611
2020's1 (1.15)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 21.30

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index21.30 (24.57)
Research Supply Index4.75 (2.92)
Research Growth Index5.47 (4.65)
Search Engine Demand Index21.17 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (21.30)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials23 (25.00%)5.53%
Reviews2 (2.17%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other67 (72.83%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]